Subscribe to Newsletter

Content by Rob Coker:

Business & Regulation Trends & Forecasts

The Battle Outside Raging

| Rob Coker | 2 min read

Climate change is real – it’s happening now – and it will take an awesome effort from the pharma industry to mitigate it

Discovery & Development Clinical Trials

Ignaz Semmelweis, We Salute You

| Rob Coker | 4 min read

In the second episode of the We Salute You series, we focus on much maligned Hungarian physician Ignaz Semmelweis

Discovery & Development Drug Discovery

Bringing Knowledge Back to Earth

| Rob Coker | 4 min read

The science behind space-based medicine is a bit of a slow-burner, but it’s on the launchpad

Manufacture Process Control

Redefining Manufacturing

| Rob Coker

Watch our roundtable discussion featuring experts from Terumo Blood and Cell Technologies, Orgenesis, ScaleReady, and BioBridge Global

Business & Regulation Business Practice

An Alliance of Giants

| Rob Coker | 4 min read

Hall Gregg, Chief Portfolio Officer at the Pistoia Alliance, discusses the transformative power of collaboration, innovation, and diversification

Manufacture Vaccines

Ditching the Egg: An Alien Concept

| Stephanie Vine, Rob Coker, Jamie Irvine | 5 min read

When it comes to influenza, chicken egg-based vaccines have achieved much, but emerging approaches are ready to fly the coop.

Discovery & Development Drug Discovery

James Phipps, We Salute You

| Rob Coker | 3 min read

It’s been 200 years since the death of Edward Jenner – but how best to celebrate his achievement?

Manufacture Advanced Medicine

The ‘Tides are Turning

| Rob Coker | 5 min read

Oligonucleotides are a complex but promising new modality in therapeutics. Director of New Modalities at CatSci Nigel Richardson explains why.

Discovery & Development Drug Delivery

International Rescue

| Rob Coker | 3 min read

The International Vaccine Institute’s Youngmi Cho is on a mission to protect communities against diseases of poverty

Manufacture Advanced Medicine

Stem Cells: The Next (Re)generation

| Rob Coker | 4 min read

CellProthera is demonstrating the safety and efficacy of a cell therapy approach to regenerating tissue following myocardial infarction

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register